NSPR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.62M

+34.5%

-0.200

+11.11%

2.36M

+54.45%

-0.205

-6.82%

3.17M

+78.52%

-0.210

-19.23%

Estimates Revision

The market is revising Upward the revenue expectations for InspireMD, Inc. (NSPR) for FY2025, with the revenue forecasts being adjusted by 1.64% over the past three months. During the same period, the stock price has changed by -25.67%.

Revenue Estimates for FY2025

Revise Upward

+1.64%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.32%

In Past 3 Month

Stock Price

Go Down

-25.67%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

Piper Sandler

Overweight

downgrade

2025-05-12

Reason

Piper Sandler

Price Target

2025-05-12

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on InspireMD to $4 from $4.50 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results with sales above its expectations. The company pushed out expectations for FDA approval for its CGuard Prime stent to Q3 2025 from the first half of 2025 due to circumstances beyond the company's control. There was also a slight wiggle to expected U.S. launch timelines for the company's SwitchGuard TCAR system in development to late 2026, Piper adds.

Valuation Metrics

The current forward P/E ratio for InspireMD Inc (NSPR.O) is -2.30, compared to its 5-year average forward P/E of -2.13. For a more detailed relative valuation and DCF analysis to assess InspireMD Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.13

Current PE

-2.30

Overvalued PE

-0.54

Undervalued PE

-3.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.39

Current EV/EBITDA

-0.34

Overvalued EV/EBITDA

0.40

Undervalued EV/EBITDA

-1.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.39

Current PS

6.45

Overvalued PS

10.74

Undervalued PS

2.04

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NSPR News & Events

Events Timeline

No data

News

3.5

2025-11-24Newsfilter

InspireMD Publishes Positive CREST-2 Data Confirming Efficacy of Carotid Stenting

1.0

2025-11-19Newsfilter

InspireMD to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler

9.5

2025-11-04NASDAQ.COM

InspireMD, Inc. Reports Wider Q3 Loss, Yet Surpasses Expectations

People Also Watch

Frequently Asked Questions

What is InspireMD Inc (NSPR) stock price today?

The current price of NSPR is 1.81 USD — it has increased 0 % in the last trading day.

What is InspireMD Inc (NSPR)'s business?

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

What is the price predicton of NSPR Stock?

What is InspireMD Inc (NSPR)'s revenue for the last quarter?

InspireMD Inc revenue for the last quarter amounts to 2.52M USD, increased 39.39 % YoY.

What is InspireMD Inc (NSPR)'s earnings per share (EPS) for the last quarter?

InspireMD Inc. EPS for the last quarter amounts to -0.17 USD, increased 6.25 % YoY.

What changes have occurred in the market's expectations for InspireMD Inc (NSPR)'s fundamentals?

How many employees does InspireMD Inc (NSPR). have?

InspireMD Inc (NSPR) has 85 emplpoyees as of January 08 2026.

What is InspireMD Inc (NSPR) market cap?

Today NSPR has the market capitalization of 76.69M USD.